First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

被引：6
|
作者：
Gettinger, S. N. [1 ]
Hellmann, M. D. [2 ]
Shepherd, F. A. [3 ]
Antonia, S. J. [4 ]
Brahmer, J. [5 ]
Chow, L. Q. [6 ]
Goldman, J. [7 ]
Juergens, R. [8 ]
Borghaei, H. [9 ]
Ready, N. E. [10 ]
Gerber, D. E. [11 ]
Nathan, F. [12 ]
Shen, Y. [13 ]
Harbison, C. T. [14 ]
Rizvi, N. [2 ]
机构：
[1] Yale Comprehens Canc Ctr, Med Oncol, New Haven, CT USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, Div Solid Tumor Oncol, New York, NY 10021 USA
[3] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Dept, Tampa, FL 33612 USA
[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Oncol, Baltimore, MD USA
[6] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA
[7] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Hematol Oncol, Los Angeles, CA 90024 USA
[8] Juravinski Canc Ctr, Dept Oncol, Hamilton, ON, Canada
[9] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA 19111 USA
[10] Duke Univ, Med Ctr, Div Oncol, Durham, NC USA
[11] Univ Texas SW Med Ctr Dallas, Div Hematol Oncol, Dallas, TX 75390 USA
[12] Bristol Myers Squibb Co, Clin Res, Princeton, NJ USA
[13] Bristol Myers Squibb Co, Biostat, Princeton, NJ USA
[14] Bristol Myers Squibb Co, Immunosci Metab Dis & Fibrosis, Princeton, NJ USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31737-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3096
引用
收藏
页码：S632 / S632
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
    Hellmann, M. D.
    Rizvi, N.
    Gettinger, S. N.
    Goldman, J.
    Chow, L. Q.
    Juergens, R.
    Borghaei, H.
    Brahmer, J.
    Shen, Y.
    Harbison, C. T.
    Nathan, F.
    Ready, N. E.
    Antonia, S. J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S633
  • [2] Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Zhong, R.
    Zhong, H.
    Zhang, B.
    Zhang, W.
    Shi, C.
    Qian, J.
    Han, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S129 - S129
  • [3] Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer
    Metzenmacher, Martin
    Christoph, Daniel C.
    [J]. JOURNAL OF THORACIC DISEASE, 2016, 8 (10) : E1254 - E1256
  • [4] Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Gettinger, Scott
    Rizvi, Naiyer A.
    Chow, Laura Q.
    Borghaei, Hossein
    Brahmer, Julie
    Ready, Neal
    Gerber, David E.
    Shepherd, Frances A.
    Antonia, Scott
    Goldman, JonathanW.
    Juergens, Rosalyn A.
    Laurie, Scott A.
    Nathan, Faith E.
    Shen, Yun
    Harbison, Christopher T.
    Hellmann, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2980 - +
  • [5] Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
    Rizvi, Naiyer A.
    Gettinger, Scott N.
    Goldman, Jonathan W.
    Hellmann, Matthew D.
    Chow, Laura Q.
    Juergens, Rosalyn
    Borghaei, Hossein
    Brahmer, Julie R.
    Shen, Yun
    Harbison, Christopher
    Nathan, Faith
    Ready, Neal
    Antonia, Scott J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S176 - S176
  • [6] Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Han, B.
    Chu, T.
    Zhang, X.
    Zhong, H.
    Zhang, B.
    Wang, H.
    Gu, A.
    Zhang, W.
    Shi, C.
    Zhong, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S398
  • [7] Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Shi, C.
    Zhong, H.
    Zhang, W.
    Zhang, B.
    Zhong, R.
    Zhang, X.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S646 - S647
  • [8] Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer
    Nishio, Makoto
    Kato, Terufumi
    Niho, Seiji
    Yamamoto, Noboru
    Takahashi, Toshiaki
    Nogami, Naoyuki
    Kaneda, Hiroyasu
    Fujita, Yuka
    Wilner, Keith
    Yoshida, Mizuki
    Isozaki, Mitsuhiro
    Wada, Shinsuke
    Tsuji, Fumito
    Nakagawa, Kazuhiko
    [J]. CANCER SCIENCE, 2020, 111 (05) : 1724 - 1738
  • [9] Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
    Merimsky, Ofer
    Cheng, Chi-Kin
    Au, Joseph Siu-Kie
    Von Pawel, Joachim
    Reck, Martin
    [J]. ONCOLOGY REPORTS, 2012, 28 (02) : 721 - 727
  • [10] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    [J]. ONKOLOGIE, 2003, 26 : 26 - 32
12345